Lilly Mounjaro KwikPen 15 MG
Lilly Mounjaro KwikPen 15 MG (Tirzepatide) is a ready-made injection pen that combines GLP-1 and GIP receptor agonists in a single formula and offers the highest dosage performance in appetite management and fat burning processes. It helps control calorie intake while supporting the metabolic rate. With the advantage of 100% original product guarantee, cold chain/protected secret packaging and fast delivery, you can place your order immediately by considering the Buy Lilly Mounjaro KwikPen 15 MG option.
$357.00 Original price was: $357.00.$310.00Current price is: $310.00.
You're now subscribed to price tracking for this product. We'll notify you if the price drops.
Tirzepatide, the active ingredient of Mounjaro, simultaneously targets two basic hunger and metabolism hormones (GIP and GLP-1) in the body. Thanks to this double mechanism of action:
-
It balances blood sugar and insulin release.
-
It provides a long-term feeling of fullness by slowing down the rate of gastric emptying.
-
It makes it easier to create a calorie deficit by suppressing appetite.
⚠️ Important Dosage Warning: 15 MG is the highest dose in the Mounjaro KwikPen series. It is not recommended to start the treatment or cycle process directly with 15 MG. It is generally recommended to start with 2.5 mg and gradually increase to 15 mg according to the body's tolerance.
Mounjaro slimming pen prices vary depending on dosage level and authenticity guarantee. It is important to choose verifiable products to protect yourself from the risks of counterfeit or improperly stored products in the market.
-
How should Mounjaro 15 MG needle be stored?
The product should be stored in the refrigerator (between 2°C - 8°C) in accordance with cold chain conditions to prevent it from losing its effectiveness.
-
Is the cargo packaging confidential?
Yes, all our shipments are shipped with 100% discreet packaging so that the contents of the packaging are never visible from the outside.













Reviews
Clear filtersThere are no reviews yet.